Skip to main content

Eversense news for Sweden and Norway. Click here to learn more

Benefits of Long-Term CGM

Eversense XL

Help Your Patients Maintain Tighter Control

  • Longer wear time

    92% industry-leading adherence across 3 pivotal trials.1-3

    Fully implantable 180-day sensor.

    Continuous readings and alerts around the clock.

    Greater insight

    Exceptional accuracy, especially in the 2.2-3.3 mmol/L range.1

    Charts, graphs and in-app reports to improve glycemic awareness.

    Three types of alerts (audio, on body vibe and mobile text) to guide safe management.


    Fewer obstacles

    No twice-monthly sensor replacement.

    Near-real time feedback to help predict and monitor trends.

    Detects 95% of hyper/hypo events in 15 minutes.1


    Improved self-management

    Exceptional 59-69% real-world time in target.1

Improved Real World Outcomes

Continuous Insights

Continuous Insights

Exceptional real-world time in target

59%-69% time in target4

Learn More
Long term

Long-Term Wear

Industry leading adherence

>23 hours of wear time1-3

Learn More

Improved Results

HbA1c reduction in pivotal studies1-3

0.5% HbA1c Reduction2

Learn More

Sign Up Your Patients Today

The Eversense XL long-term CGM System uniquely balances accuracy and discretion with an exceptional user experience.

Christiansen MP. PRECISION. Diabetes Technology & Therapeutics. Volume 21, Number 5, 2019. 2 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 3 Kropff J, Choudhary P, Neupane S, et al. PRECISE. Diabetes Care. 2017;40(1):63-68. 4 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 5 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 

MKT-001284 Rev1